Imugene Ltd has dosed the first patient in the BTKi combination cohort of its Phase 1b azer-cel study, expanding its clinical program into a global market worth about $12 billion by 2025. The patient, treated in Texas, has mantle cell lymphoma and had previously failed BTKi therapy. Azer-cel is an off-the-shelf allogeneic CAR T cell therapy aimed at advanced blood cancers with high unmet needs. This new cohort tests azer-cel combined with BTKi to evaluate safety and early efficacy in patients who relapsed after prior BTKi treatment, potentially broadening clinical applications and supporting future partnerships. The study is ongoing across 15 sites in the US and Australia, with updates expected as more data matures.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
NVIDIA and Noetra Corp. are partnering to build Japan's first national AI infrastructure, the NVIDIA Vera Rubin AI factory, featuring 13,750 Vera CPUs and 27,500 Rubin GPUs. Supported by Japan's Ministry of Economy, Trade and Industry, this 140-megaw...
Flight searches from the UK to destinations along the path of the August 12, 2026 solar eclipse have surged, with increases up to 201% for Spain's Cantabrian Coast and over 100% for Reykjavik, Iceland. This eclipse is notable as the first visible tot...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
